Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
YJ Choi, BK Roberts, X Wang, JC Geaney, S Naim… - Atherosclerosis, 2012 - Elsevier
OBJECTIVE: Determine the effects of treatment with a selective PPAR-δ agonist±statin on
plasma lipoprotein subfractions in dyslipidemic individuals. METHODS: Ion mobility analysis
was used to measure plasma concentrations of subfractions of the full spectrum of
lipoprotein particles in 166 overweight or obese dyslipidemic individuals treated with the
PPAR-δ agonist MBX-8025 (50 and 100mg/d)±atorvastatin (20mg/d) in an 8-week
randomized parallel arm double blind placebo controlled trial. RESULTS: MBX-8025 at both …
plasma lipoprotein subfractions in dyslipidemic individuals. METHODS: Ion mobility analysis
was used to measure plasma concentrations of subfractions of the full spectrum of
lipoprotein particles in 166 overweight or obese dyslipidemic individuals treated with the
PPAR-δ agonist MBX-8025 (50 and 100mg/d)±atorvastatin (20mg/d) in an 8-week
randomized parallel arm double blind placebo controlled trial. RESULTS: MBX-8025 at both …